Kaiser Permanente Medical Center
Los Angeles, California 90027
0 studies enrolling now · 11 studies all time
What they study most
COPD, Chronic Genotype 1a or 1b HCV Infection, Contrast Induced Nephropathy, Digestive System Surgical Procedures, Emphysema, HIV, HIV Infections, HIV-1 Infection, Hepatitis C Virus Infection, Hepatitis C, Chronic, Intestinal Obstruction, Kidney Diseases
Studies at this site
- LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye — Stopped early
- A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection — Stopped early
- Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults — Completed
- Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO — Completed
- Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema — Completed
- Expanded Access Program for Maraviroc At Multiple Centers — Completed
- Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery — Completed
- Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate — Completed
- Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults — Completed
- Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1 — Completed
- GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection — Completed